Kalpit Patel
Stock Analyst at B. Riley Securities
(2.07)
# 1,827
Out of 4,479 analysts
38
Total ratings
30.56%
Success rate
-0.25%
Average return
Main Sectors:
Top Industries:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $0.77 | +287.90% | 2 | Jun 18, 2024 | |
| PDSB PDS Biotechnology | Maintains: Buy | $11 → $9 | $2.95 | +205.08% | 4 | Jun 12, 2024 | |
| LBPH Longboard Pharmaceuticals | Maintains: Buy | $30 → $36 | $30.74 | +17.11% | 2 | Jun 11, 2024 | |
| VRDN Viridian Therapeutics | Downgrades: Neutral | $25 → $20 | $12.16 | +64.47% | 3 | May 9, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $1.25 | $8.42 | -85.15% | 3 | Mar 6, 2024 | |
| XFOR X4 Pharmaceuticals | Downgrades: Neutral | $3 → $1 | $0.54 | +83.72% | 1 | Dec 12, 2023 | |
| VSTM Verastem | Reiterates: Buy | $21 | $2.94 | +615.50% | 2 | Sep 29, 2023 | |
| BCYC Bicycle Therapeutics | Upgrades: Buy | $33 | $19.81 | +66.58% | 4 | Sep 12, 2023 | |
| DERM Journey Medical | Reiterates: Buy | $6 | $5.24 | +14.50% | 4 | Sep 7, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $34 → $36 | $20.66 | +74.25% | 2 | Jul 25, 2023 | |
| GERN Geron | Reiterates: Buy | $5 | $4.17 | +19.90% | 2 | Mar 20, 2023 | |
| INAB IN8bio | Downgrades: Neutral | $9 → $3 | $0.81 | +271.15% | 2 | Nov 11, 2022 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $21 → $18 | $2.16 | +733.33% | 1 | Sep 22, 2022 | |
| ENTX Entera Bio | Maintains: Buy | $6 → $5 | $1.71 | +192.40% | 1 | Jul 19, 2022 | |
| VINC Vincerx Pharma | Maintains: Buy | $12 → $6 | $0.74 | +714.11% | 2 | Jun 7, 2022 | |
| INKT MiNK Therapeutics | Maintains: Buy | $24 → $10 | $0.89 | +1,023.60% | 1 | Jan 24, 2022 | |
| KYMR Kymera Therapeutics | Initiates: Neutral | n/a | $30.22 | - | 1 | Sep 30, 2021 | |
| FBRX Forte Biosciences | Downgrades: Neutral | n/a | $0.52 | - | 1 | Sep 3, 2021 |
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.77
Upside: +287.90%
PDS Biotechnology
Jun 12, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $2.95
Upside: +205.08%
Longboard Pharmaceuticals
Jun 11, 2024
Maintains: Buy
Price Target: $30 → $36
Current: $30.74
Upside: +17.11%
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $12.16
Upside: +64.47%
Rigel Pharmaceuticals
Mar 6, 2024
Maintains: Neutral
Price Target: $1.25
Current: $8.42
Upside: -85.15%
X4 Pharmaceuticals
Dec 12, 2023
Downgrades: Neutral
Price Target: $3 → $1
Current: $0.54
Upside: +83.72%
Verastem
Sep 29, 2023
Reiterates: Buy
Price Target: $21
Current: $2.94
Upside: +615.50%
Bicycle Therapeutics
Sep 12, 2023
Upgrades: Buy
Price Target: $33
Current: $19.81
Upside: +66.58%
Journey Medical
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $5.24
Upside: +14.50%
Syndax Pharmaceuticals
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $20.66
Upside: +74.25%
Geron
Mar 20, 2023
Reiterates: Buy
Price Target: $5
Current: $4.17
Upside: +19.90%
IN8bio
Nov 11, 2022
Downgrades: Neutral
Price Target: $9 → $3
Current: $0.81
Upside: +271.15%
Allogene Therapeutics
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $2.16
Upside: +733.33%
Entera Bio
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.71
Upside: +192.40%
Vincerx Pharma
Jun 7, 2022
Maintains: Buy
Price Target: $12 → $6
Current: $0.74
Upside: +714.11%
MiNK Therapeutics
Jan 24, 2022
Maintains: Buy
Price Target: $24 → $10
Current: $0.89
Upside: +1,023.60%
Kymera Therapeutics
Sep 30, 2021
Initiates: Neutral
Price Target: n/a
Current: $30.22
Upside: -
Forte Biosciences
Sep 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.52
Upside: -